<DOC>
	<DOCNO>NCT01976312</DOCNO>
	<brief_summary>To provide efficacy safety data intravitreal injection ranibizumab 0.5 mg patient visual impairment due macular edema secondary CRVO</brief_summary>
	<brief_title>Ranibizumab Intravitreal Injections Versus Sham Control Patients With Central Retinal Vein Occlusion ( CRVO )</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>â€¢ Patients visual impairment secondary central retinal vein occlusion ( CRVO ) BCVA 24 73 letter one eye least 35 letter eye . Pregnant nursing woman woman child bear potential without use effective contraception Stroke myocard infarction within 3 month prior study History malignancy within past 5 year Uncontrolled hypertension Active infection inflammation eye monocular patient use corticosteroid least 30 day last 6 month treatment antiangiogenic drug eye within last 3 month laser photocoagulation within last month Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CRVO , macular edema , vision impairment , retinal vein occlusion , ranibizumab</keyword>
</DOC>